<DOC>
	<DOCNO>NCT00791700</DOCNO>
	<brief_summary>The primary purpose study determine pharmacokinetic property ( body maraviroc ) determine suitable dose schedule maraviroc HIV-1 infected child adolescent . This study also determine whether maraviroc safe use child adolescent .</brief_summary>
	<brief_title>An Open Label Pharmacokinetic , Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected , CCR5 -Tropic Children</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Subjects 218 year age , treatment experience 6 month longer least 2 ARV drug class , HIV1 RNA ≥1,000 copies/mL X4 dual/mixedtropic virus detect Trofile™ viral tropism assay Concomitant therapy investigational agent ( experimental ARV agent available preapproval access program ) Known ≥Grade 3 follow laboratory test Screening within 30 day prior Baseline Visit : Neutrophil count , hemoglobin , platelet , AST , ALT , creatinine , lipase ; Total bilirubin ≥Grade 3 , unless ALL following true : Current regimen include atazanavir ; ALT/AST &lt; 2.5 X ULN ; No symptom jaundice icterus . Other laboratory value ≥Grade 3 , must review Pfizer .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Open label pharmacokinetic safety efficacy HIV-1 infect pediatrics</keyword>
</DOC>